Early real-world outcomes of switching to 8 mg Aflibercept for neovascular age-related macular degeneration in the United Kingdom
Musadiq, Muiz Musadiq, Mohammed Latif, Fozia Ng, Benjamin Azzopardi, Matthew Gilead, Noa Needham, Andrew Chong, Yu Jeat
Musadiq, Muiz
Musadiq, Mohammed
Latif, Fozia
Ng, Benjamin
Azzopardi, Matthew
Gilead, Noa
Needham, Andrew
Chong, Yu Jeat
Affiliation
University of Liverpoo; Eyecare Medical; University Hospital of North Midlands; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2025-06-02
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
(1) Aim: To evaluate early real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom. (2) Methods: This retrospective, observational study included 59 eyes from 50 patients with treatment-refractory nAMD previously treated with multiple anti-vascular endothelial growth factor (anti-VEGF) agents. Eyes were switched to aflibercept 8 mg without loading doses and treated using a treat-and-extend regimen. Functional, anatomical, and safety outcomes were evaluated over a mean (SD) follow-up of 33.5 (10.4) weeks. (3) Results: The mean (SD) age was 80.2 (6.3) years, and 28 (56.0%) of 50 patients were male. At baseline, the mean (SD) best corrected visual acuity (BCVA) was 66.0 (14.4) letters, with 33 (55.9%) eyes achieving ≥70 letters. The mean (SD) baseline central subfield thickness (CST) was 367.2 (100.7) µm. Prior to switching to aflibercept 8 mg, the mean (SD) number of injections for each eye was 26.9 (19.0), with the most recent mean (SD) treatment interval of 7.7 (1.7) weeks. Switching to aflibercept 8 mg resulted in extension of the mean (SD) injection interval from 7.7 (1.7) weeks to 8.7 (2.2) weeks (p < 0.01). BCVA and CST remained stable, with a significant reduction in pigment epithelial detachment (PED) height (232.5 µm to 211.6 µm, p < 0.01). No serious ocular adverse events or intraocular pressure (IOP) elevations requiring treatment were reported. (4) Conclusion: Aflibercept 8 mg demonstrated early treatment durability, anatomical benefit, and a favourable short-term safety profile in eyes with treatment-refractory nAMD. Further prospective studies are warranted.
Citation
Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, Needham A, Chong YJ. Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life (Basel). 2025 Jun 2;15(6):903. doi: 10.3390/life1506090
Type
Article